LNTH TAUKLARIFY: Beats Tauvid, but $102.50 Buyout Caps It

The Second Tau PET Approval in History Just Happened, and Nobody Traded It

On August 14, 2026, the FDA approved TAUKLARIFY (florquinitau F 18 injection), the second tau PET imaging agent ever cleared for Alzheimer’s disease, after Lilly’s Tauvid (flortaucipir) in 2020. The decision came one day after the August 13 PDUFA date, supported by two blinded read studies covering more than 500 subjects.

Lantheus stock closed at $100.24 on August 21, barely a pulse above where it traded before the decision. There is a simple reason for the silence: Lantheus is already sold. Curium agreed on August 3 to acquire the company for $102.50 per share in cash plus up to $12 in contingent value rights. The tau PET win is now Curium’s upside, not a tradable catalyst for LNTH shareholders.

What Actually Got Approved, and What Did Not

TAUKLARIFY is indicated for PET imaging of the brain in adults with cognitive impairment being evaluated for Alzheimer’s disease, to identify tau neurofibrillary tangle pathology. It comes with a limitation of use, the standard FDA hedge for a diagnostic: a negative scan does not rule out the disease, and the tracer should be interpreted alongside clinical evaluation.

The data package is exactly what you want from an imaging agent. Two blinded read studies pulled more than 500 subjects across three trials, all dosed at roughly 185 MBq (5 mCi). Overall inter-reader agreement ran 86% to 92%, and for ruling out tau pathology, agreement reached 93% to 99%. The drug is real, the reads are reproducible, and the approval was never in doubt.

The more interesting story is the head-to-head. In the HEAD study published in The Lancet, MK-6240, the molecule now branded TAUKLARIFY, outperformed flortaucipir on the question that actually matters: discriminating Alzheimer’s-related cognitive impairment from other causes. MK-6240 posted an area under the curve of 0.93 versus 0.86 for flortaucipir (p < 0.0001), and flagged neocortical tau positivity in 28% of cognitively impaired subjects versus 16%. Flortaucipir has a known off-target binding problem: it grabs neuromelanin and monoamine oxidase, which produces false positives. MK-6240 does not.

Why Tau Matters: The Diagnose-Before-You-Treat Thesis

Tau is the pathology that correlates with cognitive decline. Amyloid plaques show up a decade before symptoms and then plateau; tau spreads through the brain roughly in lockstep with losing function. That makes tau PET the staging tool for a drug class that desperately needs staging.

The scale is not in dispute. Nearly 7 million Americans live with Alzheimer’s disease, and direct medical and care costs run past $350 billion a year. Every one of those patients who starts an amyloid drug needs confirmation first, and increasingly needs staging to know whether the treatment is worth its risk and cost.

The amyloid-targeting drugs, Leqembi and donanemab, require amyloid confirmation before treatment and work best in patients caught early, as tracked in the Leqembi post-approval coverage. Tau PET adds the second question those drugs do not answer: how far has the disease actually progressed, and is this patient likely to respond? Blood biomarkers can flag amyloid cheaply, but they are still catching up on tau. A quantitative tau tracer with better specificity than Tauvid slots directly into the treatment-selection workflow that every memory clinic is now building. That is the strategic value here, and it is why Lantheus called tau imaging essential for advancing novel treatments.

The sequence in practice is amyloid first, tau second. A patient with cognitive symptoms gets an amyloid test, and only if amyloid is positive does the clinician move to tau imaging to stage how far the disease has spread and set expectations for treatment. That ordering makes tau PET a fast-follower to amyloid PET rather than a replacement, and it is why Lantheus’s existing amyloid tracer, Neuraceq, and TAUKLARIFY are complementary products sold through the same call point instead of competing ones.

The Takeout Anchors the Stock at $102.50

This is where the analysis gets blunt. Lantheus is not a growth stock anymore; it is a merger arbitrage position.

Curium is paying $102.50 in cash at closing plus up to $12 in CVRs tied to commercial milestones through 2030. The deal was announced August 3 and is expected to close in the first half of 2027. With the stock at $100.24, LNTH trades at a 2.2% discount to the guaranteed cash portion, which is the market’s price for the risks that remain: shareholder approval, antitrust review, and the ordinary possibility of a competing bid. Analysts have flagged antitrust scrutiny because Curium and Lantheus are both major diagnostic radiopharma players.

TAUKLARIFY cannot move that price. The approval happened after the deal terms were locked, and Lantheus itself said it is still assessing the path toward broader commercial availability, which is corporate speak for no near-term revenue. What the approval does do is strengthen the CVR case. Those contingent payments ride on Lantheus product milestones through 2030, and a second approved tau tracer adds a real, if modest, future revenue stream to the pool. That is the only upside LNTH shareholders retain, and it is capped at $12 per share. Even that is not guaranteed: the CVRs are structured in $1 to $2 per share tranches tied to specific franchise thresholds, so the tau approval does not trigger a payout by itself. It only adds a product that could help clear one of those hurdles years from now.

The Competitive Picture Favors the Tracer, Not the Stock

Lantheus already owns the distribution moat. It runs the PYLARIFY PSMA PET franchise for prostate cancer imaging and Neuraceq for amyloid PET, both F18 tracers sold through the same nuclear pharmacy and manufacturing network that will carry TAUKLARIFY. PYLARIFY alone did $240.9 million in Q1 2026 revenue, down 6.5% year over year against generic PSMA-11 competition, and DEFINITY and Neuraceq round out a diagnostics engine that generates real cash flow today, not in some future launch year. That is a genuine advantage: a second-generation tau tracer plugged into existing PET infrastructure gets to market faster and cheaper than a new entrant building from scratch, exactly the drug-device hybrid economics explained in the PET imaging approval guide.

The commercial question is whether tau PET becomes a mass-market test or stays a research and specialty tool. Lilly has the first-mover label but a tracer with accuracy and off-target issues. Lantheus has the better tracer but is about to be absorbed by a private buyer. The structural disadvantage is that Lilly owns the therapeutic that drives tau demand: it sells donanemab, the amyloid drug whose prescription triggers the need for staging, and it owns Tauvid, the incumbent tracer. Lantheus brings the better tracer and the F18 distribution network but no amyloid therapeutic to pull demand through the same commercial relationship. The market for tau PET will keep growing as Alzheimer’s treatment expands, but the company that captures the most value from TAUKLARIFY’s superiority is Curium, not LNTH shareholders.

Verdict: This Is Not a Trade

Do not buy LNTH because of TAUKLARIFY. The stock is a merger arb pinned within a few points of $102.50, and the tau approval is already inside the deal price. If you want exposure to the tau thesis, the honest answers are elsewhere: Lilly owns both an amyloid drug and the incumbent tracer, and the pure-play diagnostics names are covered in the diagnostics roundup.

For anyone already holding LNTH, the decision is simple arithmetic, not science. Tender into the deal for $102.50 in guaranteed cash and treat the $12 CVR as a free option whose value you will not know until 2030, or sell now at $100.24 and give up 2.2% to avoid the regulatory and timing risk. The most accurate tau tracer on the market just changed the Alzheimer’s diagnostic picture. It did not change what Lantheus shares are worth, because that number was already set in cash.